Mylotarg, generically known as gemtuzumab ozogamicin, is a targeted cancer therapy used in the treatment of acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. It is specifically designed for patients whose cancer cells express the CD33 antigen, a common feature in AML. Mylotarg works as an antibody-drug conjugate (ADC) where an anti-CD33 antibody is linked to a cytotoxic agent. This design allows the drug to specifically target and bind to the CD33 antigen on the surface of leukemia cells, delivering the potent cytotoxic agent directly to the cancer cells, thereby killing them while sparing healthy cells. This targeted approach helps in reducing the side effects associated with traditional chemotherapy. Mylotarg was the first ADC approved by the FDA for treating AML and represents a significant advancement in the targeted treatment of this challenging disease.